AGIO - CIK 0001439222
The table below shows AGIOS PHARMACEUTICALS, INC.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$372.98M | -$389.84M | -$296.06M | -$309.48M | -$407.32M | -$290.76M |
| Capital expenditure | $4.32M | $1.69M | $999.00K | $4.88M | $5.74M | $14.11M |
| Investing cash flow | $377.18M | $363.44M | $239.57M | $243.26M | $1.25B | $75.75M |
| Dividends paid | - | - | - | - | - |
AGIOS PHARMACEUTICALS, INC. reported operating cash flow of -$372.98M for fiscal year 2025. That is up 4.3% from -$389.84M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from $38.56M (FY 2016) to -$372.98M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $8.68M | $14.44M | $5.43M | $2.35M | -$765.77M | $261.52M |